IGHE and anaphylaxis: C3H/HeJ mice with a gene deletion for murine F9 (C3H/HeJ F9−/−) develop high-titre inhibitors and fatal anaphylaxis following weekly intravenous (IV) therapy with recombinant human FIX through a combination of IgG1 and IgE formation (Verma et al, 2010).